Effect of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccination in healthcare workers with high-risk coronavirus disease 2019 (COVID-19) exposure

Selby, Laura; Hewlett, Angela; Cawcutt, Kelly; Wood, Macy G.; Balfour, Teresa; Rupp, Mark E.; Starlin, Richard

doi:10.1017/ice.2021.193

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most SARS-CoV-2 infections in vaccinated personnel occurred after higher-risk exposures to family members. As noted previously, Selby et al 6 reported that such exposures may present a substantial risk to vaccinated individuals. Our findings provide support for recommendations that vaccinated individuals continue to take measures to avoid SARS-CoV-2 exposure.…”

mentioning

confidence: 67%

“…[1][2][3][4][5] In a recent report, 5 (12%) of 43 fully vaccinated personnel acquired mildly symptomatic or asymptomatic SARS-CoV-2 infection after higher-risk household exposures. 6 Ongoing surveillance studies are needed to determine whethe such postvaccination "breakthrough" infections are caused by variants of concern with reduced in vitro susceptibility to neutralization by vaccine-induced antibodies. 7 Surveillance studies can also provide comparative data on COVID-19 in unvaccinated personnel.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans’ Affairs healthcare system

Redmond

Jones

Schmotzer

et al. 2021

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 67%

mentioning

confidence: 99%

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans’ Affairs healthcare system

Redmond

Jones

Schmotzer

et al. 2021

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

“…Smaller studies on fully vaccinated healthcare workers who subsequently developed SARS-CoV-2 infections demonstrated rates of breakthrough infection between 0.05% and 11.6%. 8 , 9 , 10 , 11…”

Section: Introductionmentioning

confidence: 99%

Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis

Mielke

Johnson

Bahl

2022

The Lancet Regional Health - Americas

View full text Add to dashboard Cite

“…Smaller studies on fully vaccinated healthcare workers who subsequently developed SARS-CoV-2 infections demonstrated rates of breakthrough infection between 0.05% -11.6%. [8][9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis

Mielke

Johnson

Bahl

2022

Preprint

View full text Add to dashboard Cite

Objective: Real-world data on the effectiveness of boosters against COVID-19, especially as new variants continue to emerge, is limited. It is our objective to assess demographic, clinical, and outcome variables of patients requiring hospitalization for severe SARS-CoV-2 infection comparing fully vaccinated and boosted (FV&B) and unvaccinated (UV) patients. Methods: This multicenter observational cohort analysis compared demographic, clinical, and outcome variables in FV&B and UV adults hospitalized for COVID-19. A sub-analysis of FV&B patients requiring intensive care (ICU) care versus non-ICU care was performed to describe and analyze common symptom presentations, initial vital signs, initial laboratory workup, and pertinent medication use in these two groups. Results: Between August 12th, 2021 and December 6th, 2021, 4,571 patient encounters had a primary diagnosis of COVID-19 and required inpatient treatment at an acute-care hospital system in Southeastern Michigan. Of the 4,571 encounters requiring hospitalization, 65(1.4%) were FV&B and 2,935(64%) were UV. FV&B individuals were older (74 [67, 81] vs 58 [45, 70]; p <0.001) with a higher proportion of immunocompromised individuals (32.3% vs 10.4%; p<0.001). Despite a significantly higher baseline risk of in-hospital mortality in the FV&B group compared to the UV (Elixhauser 16 vs 8 (p <0.001)), there was a trend toward lower in-hospital mortality (7.7% vs 12.1%; p=0.38) among FV&B patients. Other severe outcomes followed this same trend, with 7.7% of FV&B vs 11.1% UV patients needing mechanical ventilation and 4.6% vs 10.6% of patients needing vasopressors in each group, respectively (p=0.5 and 0.17). Conclusions: Fully vaccinated and boosted individuals requiring hospital-level care for breakthrough COVID-19 tended to have less severe outcomes despite appearing to be higher risk at baseline when compared to unvaccinated individuals during the same time period. Specifically, there was a trend that FV&B group had lower rates of mechanical ventilation, use of vasopressors, and in-hospital mortality. As COVID-19 continues to spread, larger expansive trials are needed to further identify risk factors for severe outcomes among the FV&B population.

show abstract

Effect of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccination in healthcare workers with high-risk coronavirus disease 2019 (COVID-19) exposure

Abstract: Appropriate precautions for fully vaccinated healthcare providers following high risk household SARS CoV-2 exposure remains unknown. Herein, we report initial results from our employee health protocol for such situations.

Cited by 5 publications

References 9 publications

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans’ Affairs healthcare system

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans’ Affairs healthcare system

Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis

Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis

Contact Info

Product

Resources

About